Keratin 8 mutations in patients with cryptogenic liver disease

New England Journal of Medicine

Volumn 344, Issue 21, 2001, Pages 1580-1587

  Ku, Nam On ^a,d   Gish, Robert ^b   Wright, Teresa L ^c   Omary, M Bishr ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; CYTOKERATIN 18; CYTOKERATIN 8; DNA; GLYCINE; HISTIDINE; HYDROGEN PEROXIDE; MUTANT PROTEIN; OKADAIC ACID; TYROSINE;

ALCOHOL LIVER DISEASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPITHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS HEPATITIS;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; CYTOSKELETON; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS; HUMANS; IMMUNOBLOTTING; KERATIN-8; KERATINS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; POINT MUTATION; RANDOM ALLOCATION; TRANSFECTION;

EID: 0035942786     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105243442103     Document Type: Article

References (52)

1. Moll R, Frank WW, Schiller DL, Geiger B, Kreple R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
2. Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 1994;63:345-82.
3. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science 1998;279:514-9.
4. Ku N-O, Zhou X, Toivola DM, Omary MB. The cytoskeleton of digestive epithelia in health and disease. Am J Physiol 1999;277:G1108-G1137.
5. Fuchs E, Coulombe PA. Of mice and men: genetic skin diseases of keratin. Cell 1992;69:899-902.
6. Steinert PM, Bale SJ. Genetic skin diseases caused by mutations in keratin intermediate filaments. Trends Genet 1993;9:280-4.
7. McLean WHI, Lane EB. Intermediate filaments in disease. Curr Opin Cell Biol 1995;7:118-25.
8. Irvine AD, McLean WHI. Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 1999;140:815-28.
9. Omary MB, Ku N-O. Intermediate filament proteins of the liver: emerging disease association and functions. Hepatology 1997;25:1043-8.
10. Magin TM. Lessons from keratin transgenic and knockout mice. Subcell Biochem 1998;31:141-72.
11. Baribault H, Price J, Miyai K, Oshima RG. Mid-gestational lethality in mice lacking keratin 8. Genes Dev 1993;7:1191-202.
12. Baribault H, Penner J, Iozzo RV, Wilson-Heiner M. Colorectal hypeplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev 1994;8:2964-73.
13. Loranger A, Duclos S, Grenier A, et al. Simple epithelium keratins are required for maintenance of hepatocyte integrity. Am J Pathol 1997;151: 1673-83.
14. Toivola DM, Omary MB, Ku N-O, Peltola O, Baribault H, Eriksson JE. Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity Hepatology 1998;28:116-28.
15. Zatloukal K, Stumptner C, Lehner M, et al. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol 2000;156:1263-74.
16. Ku N-O, Michie S, Oshima RG, Omary MB. Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant. J Cell Biol 1995; 131:1303-14.
17. Ku N-O, Michie SA, Soetikno RM, et al. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest 1996;98:1034-46.
18. Ku N-O, Wright TL, Terrault NA, Gish R, Omary MB. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest 1997;99:19-23.
19. Kulesh DA, Cecena G, Darmon YM, Vasseur M, Oshima RG. Post-translational regulation of keratins: degradation of mouse and human keratins 18 and 8. Mol Cell Biol 1989;9:1553-65.
20. Ku N-O, Omary MB. Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol 2000;149:547-52.
21. Liao I, Ku N-O, Omary MB. Two-dimensional gel analysis of glandular keratin intermediate filament phosphorylation. Electrophoresis 1996;17: 1671-6.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
23. IMP statistics and graphics guide, version 3.1. Cary, N.C.: SAS Institute, 1995.
24. 2) complexes of non-epidermal keratins isolated from cytoskeletons of rat hepatocytes and hepatoma cells. J Mol Biol 1984; 178:365-88.
25. Liao J, Lowthert LA, Omary MB. Heat stress or rotavirus infection of human epithelial cells generates a distinct hyperphosphorylated form of keratin 8. Exp Cell Res 1995;219:348-57.
26. Ohta T, Nishiwaki R, Yatsunami A, Komori A, Suganuma M, Fujiki M. Hyperphosphorylation of cytokeratins 8 and 18 by microcystin-I.R, a new liver tumor promoter, in primary cultured rat hepatocytes. Carcinogenesis 1992;13:2443-7.
27. Toivola DM, Goldman RD, Garrod DR, Eriksson JE. Protein phosphatases maintain the organization and structural interactions of hepatic keratin intermediate filaments. J Cell Sci 1997;110:23-33.
28. Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Omary MB. Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. J Cell Biol 1998;143:2023-32.
29. Raghu G, Striker L, Harlan J, Gown A, Striker G. Cytoskeletal changes as an early event in hydrogen peroxide-induced cell injury: a study in A549 cells. Br J Exp Pathol 1986;67:105-12.
30. Munoz-Marmol AM, Strasser G, Isamat M, et al. A dysfunctional desmin mutation in a patient with severe generalized myopathy. Proc Natl Acad Sci U S A 1998;95:11312-7.
31. Goldfarb LG, Park KY, Cervenakova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998;19:402-3.
32. Dalakas MC, Park K-Y, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-80.
33. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-8.
34. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:715-24.
35. Shackleton S, Lloyd DJ, Jackson SNJ, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000;24:153-6.
36. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000;9:109-12.
37. Chipev CC, Korge BP, Markova N, et al. A leucine →proline mutation in the H1 subdomain of keratin 1 causes epidermolytic hyperkeratosis. Cell 1992;70:821-8.
38. Steinert PM, Parry DAD. The conserved H1 domain of the type II keratin 1 chain plays an essential role in the alignment of nearest neighbor molecules in mouse and human keratin 1/keratin 10 intermediate filaments at the two- to four-molecule level of structure. J Biol Chem 1993;268: 2878-87.
39. Chan YM, Yu QC, Fine JD, Fuchs E. The genetic basis of Weber-Cockayne epidermolysis bullosa simplex. Proc Natl Acad Sci USA 1993; 90:7414-8.
40. Muller FB, Kuster W, Bruckner-Tuderman L, Korge BP. Novel K5 and K14 mutations in German patients with the Weber-Cockayne variant epidermolysis bullosa simplex. J Invest Dermatol 1998,111:900-2.
41. Yang J-M, Chipev CC, DiGiovanna JJ, et al. Mutations in the H1 and 1A domains in the keratin 1 gene in epidermolytic hyperkeratosis. J Invest Dermatol 1994;102:17-23.
42. Yang J-M, Nam K, Park KB, et al. A novel H1 mutation in the keratin 1 chain in epidermolytic hyperkeratosis. J Invest Dermatol 1996;107:439-41.
43. Muller T, Schafer H, Rodeck B, et al. Familial clustering of infantile cirrhosis in northern Germany: a clue to the etiology of idiopathic copper toxicosis. J Pediatr 1999;135:189-96.
44. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RAF, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997;3:359-64.
45. Kingham JGC. Dissecting out cryptogenic liver disease. Gut 2000;47: 328-9.
46. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
47. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
48. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13.
49. Covello SP, Smith FJ, Sillevis Smitt JH, et al. Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2. Br J Dermatol 1998;139:475-80.
50. Jochimsen EM, Carmichael WW, An J, et al. Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. N Engl J Med 1998;338:873-8. [Erratum, N Engl J Med 1998;339:139.]
51. Hoet P, Graf ML, Bourdi M, et al. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutions of chlorofluorocarbons. Lancet 1997;350:556-9.
52. Ponsoda X, Bort R, Jover R, Gomez-Lechon MJ, Castell JV. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem Pharmacol 1999;58:1579-85.